AFM and melanoma: In vitro studies revealed that inhibiting α4 integrin phosphorylation increased the mass flow of αLβ2-mediated T-cells, while in vivo studies found a significant increase in T-cell permeation into ectopically transplanted melanoma tumors and shrinkage of implanted B16 melanoma tumors (169).